D.B. Root & Company LLC Has $1.32 Million Stock Holdings in Stryker Co. (NYSE:SYK)

D.B. Root & Company LLC raised its position in Stryker Co. (NYSE:SYK) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,676 shares of the medical technology company’s stock after acquiring an additional 135 shares during the period. D.B. Root & Company LLC’s holdings in Stryker were worth $1,324,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of SYK. Capital Planning LLC lifted its stake in Stryker by 3.6% during the fourth quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after purchasing an additional 29 shares during the period. Alhambra Investment Management LLC lifted its position in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the period. Avestar Capital LLC lifted its position in shares of Stryker by 1.1% during the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after buying an additional 31 shares during the period. Union Savings Bank grew its position in Stryker by 1.0% in the fourth quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock valued at $1,138,000 after acquiring an additional 31 shares during the period. Finally, Patrick M Sweeney & Associates Inc. raised its stake in Stryker by 1.5% during the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock worth $793,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Stryker Trading Down 1.4 %

Shares of NYSE SYK opened at $390.31 on Thursday. The company’s 50 day simple moving average is $375.82 and its 200 day simple moving average is $360.16. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a fifty-two week low of $307.23 and a fifty-two week high of $398.20. The firm has a market capitalization of $148.79 billion, a P/E ratio of 41.83, a P/E/G ratio of 2.72 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.46 EPS. On average, analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Tuesday, December 31st. Stryker’s payout ratio is presently 36.01%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Canaccord Genuity Group upped their price objective on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Barclays raised their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Citigroup increased their price target on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average price target of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.